Allogene Therapeutics Stock Today
| ALLO Stock | USD 1.92 0.08 4.35% |
Performance0 of 100
| Odds Of DistressOver 57
|
Allogene Therapeutics is selling at 1.92 as of the 30th of January 2025; that is 4.35 percent increase since the beginning of the trading day. The stock's open price was 1.84. Allogene Therapeutics has over 57 % chance of experiencing financial distress in the next 2 years of operation and has generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 12th of March 2023 and ending today, the 30th of January 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 11th of October 2018 | Category Healthcare | Classification Health Care |
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. The company was incorporated in 2017 and is headquartered in South San Francisco, California. The company has 209.67 M outstanding shares of which 32.35 M shares are presently shorted by private and institutional investors with about 10.45 trading days to cover. More on Allogene Therapeutics
Moving together with Allogene Stock
Moving against Allogene Stock
| 0.47 | MLAB | Mesa Laboratories Earnings Call This Week | PairCorr |
| 0.41 | BMY | Bristol Myers Squibb Earnings Call This Week | PairCorr |
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Allogene Stock Highlights
| CoFounder Chairman | MD FACS | |||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||
Debt LevelsAllogene Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Allogene Therapeutics' financial leverage. It provides some insight into what part of Allogene Therapeutics' total assets is financed by creditors.
| ||||||||||||||||||||||||||
Allogene Therapeutics (ALLO) is traded on NASDAQ Exchange in USA. It is located in 210 East Grand Avenue, South San Francisco, CA, United States, 94080 and employs 232 people. Allogene Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 385.8 M. Allogene Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 209.67 M outstanding shares of which 32.35 M shares are presently shorted by private and institutional investors with about 10.45 trading days to cover.
Allogene Therapeutics currently holds about 490.49 M in cash with (237.73 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.41, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Allogene Therapeutics Probability Of Bankruptcy
Ownership AllocationAllogene Therapeutics holds a total of 209.67 Million outstanding shares. The majority of Allogene Therapeutics outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Allogene Therapeutics to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Allogene Therapeutics. Please pay attention to any change in the institutional holdings of Allogene Therapeutics as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Allogene Ownership Details
Allogene Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Geode Capital Management, Llc | 2024-09-30 | 3.2 M | |
| Wildcat Capital Management, Llc | 2024-09-30 | 2.9 M | |
| Two Sigma Investments Llc | 2024-09-30 | 2.8 M | |
| Dimensional Fund Advisors, Inc. | 2024-09-30 | 2.7 M | |
| Perceptive Advisors Llc | 2024-09-30 | 2.7 M | |
| Two Sigma Advisers, Llc | 2024-09-30 | 2.4 M | |
| Goldman Sachs Group Inc | 2024-09-30 | 2.2 M | |
| Vida Ventures Advisors, Llc | 2024-12-31 | 1.8 M | |
| Morgan Stanley - Brokerage Accounts | 2024-09-30 | 1.7 M | |
| Fmr Inc | 2024-09-30 | 30 M | |
| Tpg Gp A, Llc | 2024-09-30 | 18.7 M |
Allogene Therapeutics Historical Income Statement
Allogene Stock Against Markets
Allogene Therapeutics Corporate Management
| Timothy Moore | Executive Officer | Profile | |
| Rafael MD | Ex RD | Profile | |
| FACS FACS | CoFounder Chairman | Profile | |
| Susan Lundeen | Chief Officer | Profile | |
| Veer Bhavnagri | G Officer | Profile |
Already Invested in Allogene Therapeutics?
The danger of trading Allogene Therapeutics is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Allogene Therapeutics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Allogene Therapeutics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Allogene Therapeutics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Allogene Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Allogene Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Allogene Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Allogene Therapeutics Stock: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Allogene Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. To learn how to invest in Allogene Stock, please use our How to Invest in Allogene Therapeutics guide.You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Allogene Therapeutics. If investors know Allogene will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Allogene Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Allogene Therapeutics is measured differently than its book value, which is the value of Allogene that is recorded on the company's balance sheet. Investors also form their own opinion of Allogene Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Allogene Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Allogene Therapeutics' market value can be influenced by many factors that don't directly affect Allogene Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Allogene Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Allogene Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Allogene Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.